The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck

NCT03057613 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Pembrolizumab
RADIATION: IMRT 60-66Gy

Sponsor

Case Comprehensive Cancer Center